Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Alnuctamab +1 More for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
New Haven, Connecticut
"This trial aims to find out the right amount and timing to give alnuctamab along with mezigdomide to patients with relapsed or refractory multiple myeloma. The study will
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.